Objective To investigate the expression of stathmin and evaluate its influence to anti-microtubule adjuvant chemotherapy in non-small-cell lung cancer(NSCLC).Methods The clinical data and survival status of 78 NSCLC patients were collected,and their paraffin-embedded tissue were detected immunohistochemically with a rabbit anti-human stathmin polyclonal antibody.The clinical significance of stathmin expression and its influence to overall survival rate were analyzed statistically between patients who received paclitaxel or vinblastine adjuvant chemotherapy.Results The positive expression of stathmin could only be observed in the cytoplasm of cancer cells.Among 78 patients,40 (51.3 ％ ) patients were stained stathmin-positive.The positive rate of stathmin was significantly higher in male than female,in central type than peripheral type,in pleura-involved than non-involved,and in dead patients than survival patients ( P ＜ 0.05 ),but showed no significant differences in patients with different age,differentiated grade,pathological type,clinical stage,or lymph-node metastasis status.The expression of stathmin had a significant influence to overall survival rate(x2 =4.348,P ＜0.05 ),and those stathmin-negative patients showed a longer survival time.In stathmin-negative patients,those who received adjuvant chemotherapy with vinblastine exhibited a shorter survival time than those with paclitaxel,but the P =0.06.In stathmin-positive patients,the survival rate or time showed no difference between groups with paclitaxel and vinblastine.The differentiated grade,metastasis to lymph node and expression of stathmin were independent risk factors influencing survival rate.The positive expression of stathmin could only be observed in the cytoplasm of cancer cells.Among 78 patients,40 (51.3 ％ )patients were stained stathminpositive.The positive rate of stathmin was significantly higher in male than female,in central type than peripheral type,in pleura-involved than non-involved,and in dead patients than survival patients ( P ＜ 0.05 ),but showed no significant differences in patients with different age,differentiated grade,pathological type,clinical stage,or lymph-node metastasis status.The expression of stathmin had a significant influence to overall survival rate(x2 =4.348,P ＜ 0.05 ),and those stathmin-negative patients showed a longer survival time.In stathmin-negative patients,those who received adjuvant chemotherapy with vinblastine exhibited a shorter survival time than those with paclitaxel,but the P =0.06.In stathmin-positive patients,the survival rate or time showed no difference between groups with paclitaxel and vinblastine.The differentiated grade,metastasis to lymph node and expression of stathmin were independent risk factors influencing survival rate.Conclusion Our study suggested that the detection of stathmin in resected NSCLC tumor tissues may be helpful for prediction of prognosis,but helpless for making a choice between paclitaxel and vinblastine.NSCLC patients with stathmin-negative,no metastasis to lymph node or good-differentiated grade may have a better prognosis.%目的 探讨非小细胞肺癌(NSCLC)组织中癌蛋白18 (stathmin)的表达对抗微管化疗效果的影响.方法 收集78例NSCLC患者肺组织蜡块并随访,通过免疫组化检测stathmin蛋白的表达,分析其与临床病理指标及抗微管化疗效果的关系.结果Stathmin只表达于肿瘤细胞且定位于胞浆,阳性率51.3％(40/78例),其中男性、中央型、累及胸膜和死亡患者的阳性率较高(P＜0.05),在年龄、分化程度、淋巴结转移和临床分期等分组中差异不明显.Stathmin的表达对生存曲线的分布有影响,阴性者预后较好(x2=4.348,P＜0.05).不同化疗方案与未化疗组生存曲线的分布差异无统计学意义.Stathmin阴性者采用长春碱方案生存期较短,但差异无统计学意义(P=0.06)；阳性者中长春碱方案和紫杉醇方案差异无统计学意义.分化程度、淋巴结转移和stathmin表达是影响患者术后生存期的危险因素(P＜0.05).结论 通过免疫组化检测NSCLC手术切除标本中stathmin的表达对患者的预后估计有一定的价值,其中stathmin阴性者预后较好,但对抗微管化疗药物的选择意义不大.分化程度高、无淋巴结转移、stathmin阴性患者的预后较好.
展开▼
